<prompt> Please answer with one of the option in the bracket. Write reasoning in between . Write answer in between .Q:A 66-year-old man is brought to the emergency department 1 hour after the abrupt onset of painless loss of vision in his left eye. Over the last several years, he has noticed increased blurring of vision; he says the blurring has made it difficult to read, but he can read better if he holds the book below or above eye level. He has smoked 1 pack of cigarettes daily for 40 years. Fundoscopic examination shows subretinal fluid and small hemorrhage with grayish-green discoloration in the macular area in the left eye, and multiple drusen in the right eye with retinal pigment epithelial changes. Which of the following is the most appropriate pharmacotherapy for this patients eye condition?? A: Ustekinumab, B: Ruxolitinib, C: Cetuximab, D: Etanercept, E: Ranibizumabn,  <response>: This is a clinical vignette describing a 66-year-old male with sudden painless vision loss in his left eye. He has a history of worsening blurry vision when reading. He has a 40 pack-year smoking history. Fundus exam shows subretinal fluid, hemorrhage, and drusen in the left and right eyes, respectively. This presentation is most consistent with wet age-related macular degeneration AMD with choroidal neovascularization CNV in the left eye. The question asks about the most appropriate pharmacotherapy. The choices include biologic agents used for various conditions. Ranibizumab is an anti-VEGF medication used to treat wet AMD by inhibiting angiogenesis. The other choices are not used for AMD.E: Ranibizumab 